NCT07473089

Brief Summary

This study follows patients with infections after a joint replacement over time. During follow-up, treatment outcomes are carefully measured to determine whether the infection can be cured. In addition, factors that may change infection cure rates are examined, including the patient's overall health, the type of bacteria causing the infection, and the surgical and antibiotic treatments used. The goal is to understand what leads to more frequent cure and to improve future care.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
329

participants targeted

Target at P75+ for all trials

Timeline
42mo left

Started Sep 2022

Longer than P75 for all trials

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress53%
Sep 2022Jan 2030

Study Start

First participant enrolled

September 23, 2022

Completed
3.4 years until next milestone

First Submitted

Initial submission to the registry

March 2, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 16, 2026

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2030

Last Updated

March 16, 2026

Status Verified

March 1, 2026

Enrollment Period

7.3 years

First QC Date

March 2, 2026

Last Update Submit

March 10, 2026

Conditions

Keywords

total joint arthroplastyperiprosthetic joint infectionantimicrobial therapyinfectionfunctional outcomespatient-reported outcome measures

Outcome Measures

Primary Outcomes (1)

  • Rate of infection failure

    Rate of incident periprosthetic joint infection (according to European Bone \& Joint Infection Society criteria) or infection-related death. Types of failure include i) persistent or recurrent PJI with the same pathogen or no detected pathogen (i.e., treatment failure) and ii) a new infection caused by a pathogen different from the index episode.

    Up to 5 years. The outcome will be evaluated during the period from enrollment until the date of last clinical visit, adminstrative censoring, lost to follow-up, death; whichever occurs first.

Secondary Outcomes (8)

  • Mean of range of motion measurement (hip)

    Up to 5 years. The outcome will be evaluated during the period from enrollment until the date of last clinical visit, adminstrative censoring, lost to follow-up, death; whichever occurs first.

  • Mean of range of motion measurement (knee)

    Up to 5 years. The outcome will be evaluated during the period from enrollment until the date of last clinical visit, adminstrative censoring, lost to follow-up, death; whichever occurs first.

  • Percent using any analgesics

    Up to 5 years. The outcome will be evaluated during the period from enrollment until the date of last clinical visit, adminstrative censoring, lost to follow-up, death; whichever occurs first.

  • Percent using walking aids (for lower extremity)

    Up to 5 years. The outcome will be evaluated during the period from enrollment until the date of last clinical visit, adminstrative censoring, lost to follow-up, death; whichever occurs first.

  • Mean of EuroQol five-dimensional questionnaire score

    Up to 5 years. The outcome will be evaluated during the period from enrollment until the date of last clinical visit, adminstrative censoring, lost to follow-up, death; whichever occurs first.

  • +3 more secondary outcomes

Interventions

Participants who undergo revision surgery of a prosthetic hip, knee, shoulder, ankle, or elbow joint for suspected periprosthetic joint infection. A patient may contribute one or more episodes, which are defined as a condition leading to revision surgery for a suspected or confirmed periprosthetic joint infection.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants who undergo revision surgery of a prosthetic hip, knee, shoulder, ankle, or elbow joint for suspected periprosthetic joint infection.

You may qualify if:

  • ≥18 years of age
  • Revision surgery of any large prosthetic joint (i.e., hip, knee, shoulder, ankle, or elbow) performed for a suspected or confirmed periprosthetic joint infections at any of the participating study centres. This includes patients who were previously treated at another hospital and referred to a participating study centre if data on a transferred patient from the previous institution are available, complete, and archived in the institutional patient information system, and the patient underwent at least one surgery at a participating institution.
  • Obtained written informed consent
  • Periprosthetic joint infections diagnosis likely or confirmed according to European Bone and Joint Infection Society criteria

You may not qualify if:

  • Documented objection to subsequent use of personal health data
  • Patient follow-up outside of Switzerland
  • Diagnosis "periprosthetic joint infections unlikely" according to European Bone and Joint Infection Society criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Department of Infectious Diseases and Infection Prevention, Cantonal Hospital Aarau

Aarau, Switzerland

RECRUITING

Department of Infectious Diseases, Bern University Hospital

Bern, Switzerland

RECRUITING

Department of Medicine, HFR Fribourg-Hôpital Cantonal

Fribourg, Switzerland

RECRUITING

Orthopedic Surgery Service, Geneva University Hospitals

Geneva, Switzerland

RECRUITING

Department of Medicine, Lausanne University Hospital

Lausanne, Switzerland

RECRUITING

Related Publications (4)

  • Vuorinen M, Makinen T, Rantasalo M, Huotari K. Effect of a multidisciplinary team on the treatment of hip and knee prosthetic joint infections: a single-centre study of 154 infections. Infect Dis (Lond). 2021 Sep;53(9):700-706. doi: 10.1080/23744235.2021.1925341. Epub 2021 Jun 1.

    PMID: 34060985BACKGROUND
  • Karczewski D, Winkler T, Renz N, Trampuz A, Lieb E, Perka C, Muller M. A standardized interdisciplinary algorithm for the treatment of prosthetic joint infections. Bone Joint J. 2019 Feb;101-B(2):132-139. doi: 10.1302/0301-620X.101B2.BJJ-2018-1056.R1.

    PMID: 30700114BACKGROUND
  • Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR; Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013 Jan;56(1):1-10. doi: 10.1093/cid/cis966.

    PMID: 23230301BACKGROUND
  • Koh CK, Zeng I, Ravi S, Zhu M, Vince KG, Young SW. Periprosthetic Joint Infection Is the Main Cause of Failure for Modern Knee Arthroplasty: An Analysis of 11,134 Knees. Clin Orthop Relat Res. 2017 Sep;475(9):2194-2201. doi: 10.1007/s11999-017-5396-4. Epub 2017 Jun 1.

    PMID: 28573549BACKGROUND

MeSH Terms

Conditions

Infections

Interventions

Second-Look Surgery

Intervention Hierarchy (Ancestors)

Surgical Procedures, Operative

Study Officials

  • Nora Renz

    Inselspital, Universitätsspital Bern

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 2, 2026

First Posted

March 16, 2026

Study Start

September 23, 2022

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Last Updated

March 16, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

Interested researchers can access all available data if a study proposal is approved by the Swiss Revision Cohort scientific board.

Shared Documents
STUDY PROTOCOL, ICF, CSR, ANALYTIC CODE
Time Frame
Unending

Locations